Integer Holdings Corporation ITGR

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

PLANO, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading global medical device contract development and manufacturing organization (CDMO), today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with the previously announced acquisition of Integer by an affiliate of investment funds managed by KKR (the “Me

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Integer Holdings (NYSE:ITGR) and its peers.

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

KKR has fallen sharply this year, even after a strong multi year run. This puts fresh focus on whether the current US$100 share price still lines up with what its earnings can support. With the stock moving and the deal pipeline active, investors are asking how much of KKR's profit engine is already reflected in today's valuation. Over the past 5 years the share price has gained 64.1%. As a result, a lot of long term value creation is already being tested against the strength and resilience...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 26.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

KKR (KKR) is in focus after reports that it is nearing a takeover of medical device outsourcer Integer Holdings for about $4.3 billion, with an indicated offer of $127 per share. See our latest analysis for KKR. At a share price of US$105.65, KKR has recently shown firm short term momentum with a 7 day share price return of 6.42% and 30 day return of 10.09%. However, the year to date share price return is down 18.04% and the 1 year total shareholder return is down 26.43%. This is set against...

The updated analyst model for Integer Holdings now points to a fair value of US$112.14, up from US$97.56, which reflects a roughly 15% uplift in the price target. Much of this shift ties back to fresh Street commentary following KKR’s agreed all cash offer of US$127 per share, with analysts reframing views around the stock through the lens of deal terms and closing risk. As you read on, you will see how this new price target fits into the evolving narrative around Integer Holdings and what it...

Shares of medical technology company Integer Holdings (NYSE:ITGR) jumped 2.7% in the afternoon session after the company agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion, while also reporting second-quarter results that topped Wall Street expectations.

Integer Holdings (ITGR) has moved into the spotlight after reporting second quarter 2026 earnings alongside a pending all cash acquisition by KKR. Both updates give you fresh information to assess the stock. See our latest analysis for Integer Holdings. Integer Holdings shares have reacted sharply to the proposed US$127 per share cash offer, with a 7 day share price return of 23.98% and a 90 day share price return of 44.22%, while the 5 year total shareholder return of 38.00% highlights a...

Completion of the deal is subject to shareholder and regulatory approvals and is anticipated by the end of the year.